Table 1.
Clinical data, biochemical data, metastatic calcification, and outcomes in the two groups
| FFgroup (n = 59) |
Control group (n = 295) |
p value | |
|---|---|---|---|
| BMI | 22.89 (19.48, 25.08) | 22.66 (20.18, 24.71) | 0.984 |
| Glucocorticosteroid treatment,n (%) | 14 (3.7) | 108 (36.6) | 0.08 |
| Primary hypertension,n (%) | 28 (47.5)a | 89 (30.2) | 0.042 |
| Diabetes,n (%) | 27 (45.8)a | 95 (32.2) | 0.045 |
| Hemoglobin, g/L | 102.0±24.14a | 93±25.0 | 0.012 |
| Prealbumin, mg/L | 126.15±20.15 | 129.14±20.06 | 0.298 |
| Albumin, g/L | 36.3±5.90 | 36.3±5.91 | 0.968 |
| TC, mmol/L | 3.55 (3.06, 4.16)a | 4.02 (3.34, 4.75) | 0.019 |
| TG, mmol/L | 1.29 (1.01, 1.70) | 1.26 (0.92, 1.86) | 0.846 |
| LDL, mmol/L | 1.87 (1.45, 2.46)b | 2.21 (1.70, 2.96) | 0.007 |
| HDL, mmol/L | 1.13±0.35 | 1.23±0.38 | 0.084 |
| LP-α, mg/L | 234 (106.0, 445.0)a | 405 (184.8, 561.8) | 0.015 |
| ALP, U/L | 99.0 (70.0, 173.0)a | 86.0 (67.0, 114.0) | 0.014 |
| Calcium, mmol/L | 2.19 (2.03, 2.32)c | 2.10 (1.87, 2.20) | 0.000 |
| Corrected calcium, mmol/L | 2.27 (2.15, 2.42)b | 2.18 (2.00, 2.30) | 0.000 |
| Phosphorus, mmol/L | 1.60 (1.24, 1.81) | 1.76 (1.37, 1.98) | 0.060 |
| iPTH, pg/mL | 207.9 (134.0, 448.7)b | 362.5 (222.4, 503.5) | 0.002 |
| Calcium-phosphorus product, mmol2/L2 | 3.63 (2.71, 4.25) | 3.60 (2.91, 4.27) | 0.594 |
| Aortic calcification,n (%) | 32 (54.2)b | 94 (31.9) | 0.002 |
| Cardiac valve calcification,n (%) | 17 (28.8)a | 43 (14.6) | 0.013 |
| All-cause death,n (%) | 34 (57.6)c | 51 (17.3) | 0.000 |
| CV events,n (%) | 26 (44.1)a | 85 (28.8) | 0.017 |
CV events include stable or unstable angina, myocardial infarction, heart failure, transient ischemic attack, cerebral ischemic stroke and subarachnoid hemorrhage, cerebral hemorrhage, peripheral arterial diseases, abdominal aortic aneurysm, arrhythmia, and sudden cardiac death.
a
p < 0.05 versus control group;
b
p < 0.01 versus control group;
c
p < 0.001 versus control group.